Anti-tumor
We focus on the develoment of new drugs in the field of common and hostile cancers.Our innovative medicine programs in clinical trials include HS-20106 injection, HS-20105 injection, HS-20117 injection, HS-10516 capsules, HS-10382 tablets, HS-10370 tablets, HS-10502 tablets, HS-10365 capsules, HS-20089 injection, HS-20093 injection, HS-20124 injection, HS-10352 tablets, HS-10241 tablets, HS-10504 tablets, etc.Our product portfolio mainly includes the innovative drug Ameile (aumolertinib mesylate tablets), the innovative drug Hansoh Xinfu (flumatinib mesylate tablets), Pulaile (pemetrexed disodium for injection), Xintai (bortezomib for injection) ,Xinwei (imatinib mesylate tablets) and Tanneng (fosaprepitant dimeglumine for injection).